A disease is known as “emerging” when its human incidence has increased over the past two decades; this is the case of AIDS, Flaviviruses, Chikungunya, Zika and Dengue, among others. These diseases correspond to the appearance of "new pathogenic germs or the re-emergence of old diseases. The causes of these emergences are multiple, such as the increase in the number of travellers around the world, the emergence of antibiotic resistance, and global warming. According to the WHO report, these emerging diseases account for 33 % of deaths worldwide. The objective of the MIP-FISH (Infectious Diseases and Pharmacology on Zebrafish) project is to establish an in vivo animal model compatible with the constraints of P3 laboratory experimentation and the associated financial costs. This model will decorate the infectious processes behind the development of these diseases and the identification of new drugs. The MIP-FISH project is supported by the CNRS, via the CEMIPAI (Centre for the Study of Infectious Diseases and Pharmacology Anti-Infectious Diseases), a joint unit of the CNRS and the University of Montpellier, specialising in the understanding of infectious processes (safety level 3) and the search for new anti-infectious or diagnostic treatments. AZELEAD, an SME located in Montpellier, is associated with the project.